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Abstract
Mitoxantrone is an anthracycline used as an antitumour antibiotic for leukaemia and breast cancer treatment, due to its
interaction with DNA. However, the molecular mechanism of the antitumour action is not completely understood. Using a
glassy carbon electrode the electrochemical oxidation of mitoxantrone was shown to be a complex, pH-dependent, irreversible
electrode process involving several metabolites. Comparison of the electrochemical oxidation behaviour of mitoxantrone,
ametantrone and aminantrone enabled a deeper understanding of the mechanism and showed the relevance of electrochemical
data for the understanding of the cytotoxicity of mitoxantrone. Since mitoxantrone and its oxidation products adsorb strongly
on the electrode surface, causing severe problems of electrode fouling, reproducible electroanalytical determinations could
only be done at very low concentrations and in an aqueous buffer supporting electrolyte containing 30% ethanol. The detection
limit obtained was 10ÿ7 M. # 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Mitoxantrone (1,4-dihydroxy-5,8-bis[[2-[(2-hydro-
xyethyl)amino]ethyl]amino]-9,10-anthracenedione)
(MTX) is an aminoanthraquinone, an anthracycline
antibiotic, used as an antitumour antibiotic, due to its
interaction with DNA [1]. It has a planar heterocyclic
ring structure, the positively charged, nitrogen-con-
taining side chains projecting out from the molecule,
which stabilize the ring in between base pairs by
intercalating with the negatively charged phosphate
backbone of DNA [2,3]. Originally synthesized as
stable dyes [3–5], anthracenediones are used as anti-
tumour antibiotics for leukaemia and breast cancer
treatment. MTX has been shown to induce condensa-
tion of nucleic acids but the most dominant molecular
mechanism of antitumour action appears to be the
induction of long-term DNA damage. Cytotoxic
effects, although less than for other anticancer drugs,
cause myelosuppression, cardiac toxicity and muco-
sitis as well as other common effects. The mechanism
of action of MTX is not completely understood but
studies with an electrochemical DNA-biosensor [6],
enabled the observation of DNA damage occurring
with time which suggests that MTX intercalates with
DNA and slowly interacts with it causing some break-
ing of the hydrogen bonds.
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It was demonstrated that MTX is easily oxidized
either by horseradish peroxidase producing free radi-
cals that will bond to DNA [7,8] or by a myeloper-
oxidase [9,10] producing reactive intermediates. The
substituents on MTX that are susceptible to oxidation
are the hydroxyl and amino groups on the aromatic
rings. The 5,8-hydroxyl substituents on the MTX
anthracenedione chromophore are available to interact
with the double helix [11]. Experiments with two
anthraquinone derivatives structurally related to
mitoxantrone, ametantrone and aminantrone [12–
14], have been undertaken to assess the influence of
the hydroxyl groups on the oxidation process. Both
these compounds lack the hydroxy substituents at
positions 5 and 8 and differ by the presence or absence
of hydroxyethyl groups on the aminoalkyl side chains
(see Scheme 1).
The electrochemical reduction and oxidation of
MTX have been studied but the mechanism was not
fully established and detection limits at the nonmolar
level were achieved using carbon paste electrodes only
when a preconcentration time of 4 min was used and
the electrode was polished between each measurement
[12,15,16].
In this paper the electrochemical oxidation mechan-
ism of MTX will be discussed and clarified by also
studying the electrochemical oxidation of AMET and
AMIN-1. It is hoped that this investigation may con-
tribute to a better understanding of the cytotoxicity of
MTX, which is also electroanalytically quantified in
aqueous solution, without preconcentration, using a
glassy carbon electrode.
2. Experimental
Mitoxantrone (MTX) (dihydroxyanthracenedione)
was a synthetic sample solution of Novantrone1
(mitoxantrone hydrochloride) that was supplied by
Lederle Laboratories, Gosport, UK. The MTX sample
stock solution of 2 mg mlÿ1 (4.510ÿ3 M) was kept
away from light to avoid photodecomposition and at a
temperature of38C. Solutions of 10ÿ4 M MTX were
always prepared just before the experiments from the
sterilized stock solution. Solutions of 10ÿ4 M ametan-
trone (AMET) and aminantrone (AMIN-1) were pre-
pared from the stock solution just before the
experiments.
The universal 0.3 M ionic strength buffer was pre-
pared by mixing 0.8 M NaOH, 1.34 M KCl and an
acid solution (0.16 M acetic acid, 0.16 M phosphoric
acid and 0.16 M boric acid). All reagents were analy-
tical grade and aqueous solutions were prepared using
purified water from a Millipore Milli-Q system (con-
Scheme 1.
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ductivity (0.1 ms cmÿ1). The pH measurements were
obtained with a Crison 2001 pH-meter with a com-
bined glass electrode. All experiments were done at
room temperature.
Voltammograms were recorded using a mAutolab
potentiostat/galvanostat running with GPES version 3
software, from Eco-Chemie, Utrecht, Netherlands. A
three-electrode cell with a glassy carbon working disc
Fig. 1. Cyclic voltammograms for MTX in 0.3 M universal buffer in: (a) pH 8.09: 110ÿ4 M and 2–2.2510ÿ5 M; (b) pH 7.25: 110ÿ5 M.
Scan rate 200 mV/s.
Fig. 2. Square wave voltammograms of MTX, 110ÿ5 M in pH 1.13, 0.1 M perchloric acid: (———) net current and (. . .) IfÿIb. Frequency
100 Hz.
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electrode (1 mm diameter, Cypress Systems, Lawr-
ence, Kansas, USA) together with an Ag/AgCl (3.0 M
KCl) reference electrode, and a Pt-wire counter elec-
trode were employed. The glassy carbon working
electrode was polished using diamond spray (3 mm).
After polishing, the electrode surface was thoroughly
washed with purified water. All electrodes were con-
tained in a one-compartment cell. Differential pulse
voltammetry conditions were: pulse amplitude
100 mV, pulse width 70 ms and scan rate 5 mV sÿ1.
Square wave voltammetry conditions were: frequency
100 Hz, pulse amplitude 50 mV and scan increment
2 mV, corresponding to an effective scan rate of
200 mV sÿ1.
3. Results and discussion
The electrochemical oxidation mechanism of MTX
is a multistep process involving generation of free
radicals and structural rearrangements as both the
hydroxyl and the amino groups substituents on the
aromatic rings of MTX are susceptible to oxidation
(Figs. 1 and 2). MTX is a weak base with pKa15.99
[17] and pKa28.13 [18,19].
Cyclic voltammograms of MTX, Fig. 1, showed
that the complex electrochemical oxidation at a glassy
carbon electrode is an irreversible electrode process.
The first oxidation peak corresponds to the oxidation
of the hydroxyl substituents at positions 5 and 8 and
the second peak to the oxidation on the aminoalkyl
side chains after a tautomeric structural rearrangement
[15]. This was further investigated using differential
pulse voltammetry and square wave voltammetry. In
fact the first oxidation step is reversible, which is
easily confirmed if the scan is stopped at a E0.57 V
just before the beginning of the second oxidation peak
(Fig. 1(b)) and has also previously been observed
[15]. Square wave voltammograms (Fig. 2) show
the net current and the difference between the forward
and backward currents; the reversibility of the first
oxidation step is very clearly demonstrated in pH 1.13,
0.1 M perchloric acid, supporting electrolyte.
The electrochemical oxidation of MTX was also
studied using square wave voltammetry for a wide
range of pH (1.1–12.8), and it followed a two electron
two proton transfer pathway over all the pH range
studied (Fig. 3(a)). The peak currents diminished with
increasing pH and the peaks almost disappeared for
pH values higher than 9 (Fig. 3(b)).
In order to clarify the electrochemical mechanism
and to assess the influence of the hydroxyl groups on
Fig. 3. (a) Plot of Ep vs pH for 10
ÿ5 M solutions of MTX in 0.3 M
universal buffer electrolyte. Dotted line corresponds to a slope of
59 mV per unit of pH. Frequency 100 Hz. (b) 3D plot of square
wave voltammograms as a function of pH.
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Fig. 4. Differential pulse voltammograms in 0.3 M universal buffer electrolyte of 110ÿ5 M of MTX (———), AMET (. . .) and AMIN-1 (- - -): (a) pH 1.8; (b) pH 4.7 and (c) pH
7.3. Frequency 100 Hz.
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the oxidation process, the electrochemical oxidation
of MTX was compared with the electrochemical
oxidation, at the same glassy carbon electrode, of
the two anthraquinone derivatives structurally related
to MTX: AMETand AMIN-1 and for pH values of 1.8,
4.7 and 7.3 (Fig. 4(a), (b) and (c)). These both com-
pounds lack the 5,8-hydroxyl substituents on the MTX
and AMIN-1 also has no hydroxyl substituents on the
side chain. The oxidation of AMET and AMIN-1 can
occur only at the aminoalkyl substituent. This is at a
more positive potential than the first oxidation peak of
MTX, which corresponds to the oxidation of the 5,8-
hydroxyl substituents, and at a similar potential to the
second oxidation peak of MTX, corresponding to the
oxidation of the aminoalkyl substituents.
As a resulting of these comparative studies, the
detailed mechanism proposed for the electrochemical
oxidation of MTX can be described by the reactions
given in Scheme 2.
The oxidation of 5,8-hydroxyl substituents on MTX
(reaction (a)) corresponding to the first reversible
oxidation peak of the voltammograms occurs at less
positive potentials. This peak does not occur for
AMET and AMIN-1 which is in agreement with their
molecular structure not having 5,8-hydroxyl substitu-
ents. A tautomeric equilibrium (reaction (b)) was
proposed [18] to explain the formation of a tautomer,
where the intramolecular addition of the side chain
nitrogen was favoured, and which corresponds to the
second oxidation peak. After the tautomeric structural
Scheme 2.
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rearrangements, oxidation of the aminoalkyl substi-
tuent in MTX (reaction (c)) yields the stable metabo-
lite cyclic hexahydronaphthol-[2,3-f]-quinoxaline-
7,12-dione (MH2) and the reaction proceeds via for-
mation of free radical species from MH

2 leading to
further conversion to an unstable, fully oxidized dii-
mino compound (MH22 ), which shows electrophilic
character [18,19] and has been structurally identified
[20,21]. So far 10 metabolites of the MTX oxidation
have been identified but the structures of many of them
are still unknown. Fig. 4 shows that the oxidation of
the aminoalkyl substituents in AMETand AMIN-1 is a
multistep process with the kinetics of the electron
transfer mechanism being pH-dependent and with the
possible formation of intermediate radicals and dimer-
ization products.
The quantitative analysis of MTX is complicated
because of the instability of this drug in plasma at
room temperature, nonspecific binding of mitoxan-
trone to proteins, and (in aqueous solutions) adsorp-
tion onto many materials, including filters and glass
surfaces. Its oxidation and reduction products also
adsorb strongly on the electrode surface causing
severe problems of electrode fouling [12,15,16].
In fact, MTX adsorbs very strongly on the electrode
surface as soon as it is immersed in the MTX/support-
ing electrolyte solution, and in order to minimize this
effect, 30% ethanol was added to the supporting
electrolyte which causes a much slower adsorption
of the drug on the electrode surface but does not
change the electrochemical reaction. This effect of
increasing peak height and decreasing peak width in
square wave voltammograms, is shown in Fig. 5.
Electroanalytical quantification of MTX was done
in this mixed supporting electrolyte using square wave
voltammetry in the range of 10ÿ7–10ÿ5 M (Fig. 6). It
was not necessary to clean the electrode between
experiments. From the square wave voltammograms
of the standards, a straight line calibration plot was
obtained between 10ÿ7M and 10ÿ6 M, described by
the equation I(mA)0.546 [MTX]/mMÿ0.00479
(r0.996, n6), for MTX and the detection limit
was 10ÿ7 M, based on three times the noise level.
4. Conclusions
The electrochemical oxidation of mitoxantrone is a
complex irreversible electrode process that is pH-
dependent and involves several metabolites. Compar-
Fig. 5. Square wave voltammograms of MTX, 10ÿ5 M in pH 1.13,
0.1 M perchloric acid, (———) with 30% ethanol and (. . .) without
ethanol. Frequency 100 Hz.
Fig. 6. Sucessive square wave voltammograms in 0.3 M universal
buffer electrolyte pH 2.03 of MTX with 30% ethanol: (1) 0.19; (2)
0.39; (3) 0.57; (4) 0.99; (5) 1.88; (6) 2.76; (7) 4.45; (8) 6.12; (9)
10 mM. Frequency 100 Hz.
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ison of the electrochemical oxidation behaviour of
mitoxantrone, ametantrone and aminantrone enables a
deeper understanding of the mechanism and shows the
relevance of the electrochemical data for the under-
standing of the cytotoxicity of MTX.
Both mitoxantrone and its oxidation products
adsorb strongly on the electrode surface causing
severe problems of electrode fouling. Electroanalyti-
cal determinations could be done only for very low
concentrations and in an aqueous buffer supporting
electrolyte containing 30% ethanol. The detection
limit was 10ÿ7 M.
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